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Abstract: Gestational diabetes mellitus (GDM) is associated with poor pregnancy outcomes and
increased long-term risk of metabolic diseases for both mother and child. In Tanzania, GDM prevalence
increased from 0% in 1991 to 19.5% in 2016. Anaemia has been proposed to precipitate the pathogenesis
of GDM. We aimed to examine the prevalence of GDM in a rural area of Tanzania with a high prevalence
of anaemia and to examine a potential association between haemoglobin concentration and blood
glucose during pregnancy. The participants were included in a population-based preconception,
pregnancy and birth cohort study. In total, 538 women were followed during pregnancy and scheduled
for an oral glucose tolerance test (OGTT) at week 32–34 of gestation. Gestational diabetes mellitus
was diagnosed according to the WHO 2013 guidelines. Out of 392 women screened, 39% (95% CI:
34.2–44.1) had GDM, the majority of whom (94.1%) were diagnosed based solely on the fasting blood
sample from the OGTT. No associations were observed between haemoglobin or ferritin and glucose
measurements during pregnancy. A very high prevalence of GDM was found in rural Tanzania.
In view of the laborious, costly and inconvenient OGTT, alternative methods such as fasting blood
glucose should be considered when screening for GDM in low- and middle-income countries.
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1. Introduction
The prevalence of gestational diabetes mellitus (GDM) is increasing worldwide [1]. Since GDM
is associated with a higher risk of adverse pregnancy outcomes as well as with long term adverse
consequences for both mother and child including an increased risk of developing metabolic diseases
such as type 2 diabetes [2,3], it is important to identify these high-risk women. Today, few studies have
examined the prevalence of GDM in Sub-Saharan Africa (SSA) and diagnosis remains sub-optimal due
to associated logistical and cost barriers for resource-constrained populations [4]. A systematic review
from 2015 reported prevalence rates up to 14% of GDM but with high heterogeneity between studies [5].
A recently published systematic review and meta-analysis concluded that the pooled prevalence of
GDM in Africa was 13.6%, with the highest prevalence in Central Africa (20.4%) and the lowest in
Northern Africa (7.6%), estimated by using the current International Association of the Diabetes and
Pregnancy Study Groups (IADPSG) diagnostic criteria [6]. In Tanzania, GDM prevalence ranged from
0% in a rural areas in 1991 when applying WHO 1985 criteria [7], to 19.5% in urban areas in 2016 using
the WHO 2013 criteria [8]. Furthermore, a study from 2012 showed that the prevalence seems to be
dependent on living conditions, with a GDM prevalence of 8.4% in urban areas and 1.0% in rural areas
in Tanzania using WHO 1999 criteria [9]. Diagnostic criteria have varied and comparing reports of
GDM prevalence across studies can be challenging, but the prevalence seems to have increased over
time. Several factors such as pre-pregnancy body mass index (BMI), family history of diabetes, age and
glycosuria are all associated with higher risk of developing GDM, but anaemia has also been proposed
as playing a role in the GDM pathogenesis [10]. Even though the worldwide prevalence of anaemia
has slightly decreased in the last decade, the prevalence in 2011 was above 50% in Central and West
Africa and 36% in East Africa among pregnant women [11]; the corresponding figures in Tanzania
were 40%–59% [12]. Iron deficiency is the most common nutritional cause of anaemia. Anaemia is
usually assessed by haemoglobin (Hb) concentration and iron deficiency by ferritin concentration [13].
In the present study, we aimed to examine the prevalence of GDM in a rural area of Tanzania
using a standard oral glucose tolerance test (OGTT), and to examine whether there is an association
between Hb and ferritin concentrations in pregnancy and risk of developing GDM.
2. Subjects
The participants were included in a large population-based study named FOETALforNCD (Foetal
exposure and Epidemiological Transition: the role of Anaemia in early Life for Non-Communicable
Diseases in later life) [14]. All participants were residents in the rural Korogwe and Handeni districts
in Tanga region, Northeast Tanzania. Mobile clinics were set up in 48 villages in the two districts and
seventeen dispensaries functioned as outreach satellite sites. The study population were enrolled from
July 2014 to March 2016 and consisted of two different groups. One group (n = 383) was enrolled
before pregnancy and conceived during the study period. For the pre-pregnancy cohort the inclusion
criteria were; an age between 18–40 years; a negative urine pregnancy test; no usage of modern
contraceptive methods except condoms; not having a child less than nine months old; living in an
accessible area; and upon conception, willingness to attend antenatal care and give birth at Korogwe
district hospital. Women having tried to conceive unsuccessfully for more than two consecutive years
(regarded as infertile) were excluded. When conceiving they were enrolled in the pregnancy part of
the study irrespective of their Hb levels. The other group consisted of 155 pregnant women, who were
recruited ≤14 gestational weeks based on the degree of anaemia; with severe anaemia: Hb ≤ 8 g/dL
[4.96 mmol/L], mild-moderate anaemia: Hb 8.1–10.9 g/dL [5.02–6.81 mmol/L] or without anaemia:
Hb ≥ 11 g/dL [6.82 mmol/L], Figure 1.
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distributed during pregnancy, at week 20–22, week 26–28, week 32–34 and week 37–39. At all 
antenatal visits, the women were monitored for anaemia (Hb < 11 g/dL), infections including malaria, 
hypertensive disorders and anthropometric measurements were also collected. Weight was 
measured while barefooted and wearing light clothes on a digital weighing scale. Height in 
centimetres was measured with a stadiometer and BMI was defined as weight in kilograms divided 
by the square of the height in meters (kg/m2). Mid-upper arm circumference (MUAC) was measured 
on the upper right arm at the midpoint of the acromion process and the tip of the olecranon. Blood 
pressure was measured by a digital blood pressure monitor (r-champion® N, Rudolf Riester, 
Jungingen, Germany) with an inflatable cuff of an appropriate size after resting for at least 5 min [17]. 
Furthermore, the women were screened with a urine dipstick for glucosuria as well as for 
polyhydramnios (defined as an amniotic fluid index > 20) with transabdominal ultrasound. 
In total, 538 women were included in the present study, of whom 392 women were screened 
with an OGTT, with the majority being screened during weeks 32–34 of gestation. The OGTT was 
scheduled for the antenatal visit in week 32–34, due to concerns about missing women with GDM if 
they were screened at the previous visit in week 26–28. Most of the women had their visits in the first 
available week, i.e., week 26 and week 32. Out of the 538 women, 77 had a miscarriage, 34 moved 
outside the study area or withdrew their consents and the remaining 35 women either did not comply 
with the overnight fasting criterion before the examination, missed their visit in the last trimester or 
gave birth before week 32 (Figure 1). No differences in age, BMI, MUAC or Hb was observed between 
the women who underwent an OGTT and the ones that were not tested (data not shown). 
The OGTT was performed after 12-h of overnight fasting. Venous fasting blood samples were 
taken and blood from the butterfly blood sampling tube was used to measure glucose immediately 
using HemoCue® Glucose 201 RT (Ängelholm, Sweden). The coefficient of variation for the HemoCue 
Glucose 201 has previously been shown to be 1.8%, and is almost as precise as the hexokinase 
laboratory method [18]. 
Hereafter, each woman was instructed to drink a glucose solution containing 82.5 g 
monohydrate glucose (corresponding to 75 g anhydrous glucose) (Rapra’s Pure Glucose, Instant 
Energy Plus, Rapra Limited, Nairobi Kenya) in 250 mL of water within 5 min. Thereafter, she was 
instructed to be seated in the waiting area without drinking, eating or smoking for the following 2 h, 
where blood glucose was measured by a fingerprick test after 1- and 2-h. If the OGTT was abnormal, 
the women were given dietary advice and were controlled every third week for fasting blood glucose 
and glycated haemoglobin (HbA1c) (Afinion AS 100 analyzer). If the women by mistake had not been 
Figure 1. Overview of the recruitment of the study cohort. OGTT: Oral glucose tolerance test.
3. Materials and Methods
The study has been described in details elsewhere [14] but in short, at inclusion, information
on ethnicity and socioeconomic status was obtained. Gestational age was estimated by crown rump
length in the first trimester and head circumference in the second trimester using transabdominal
ultrasound (5–2 MHz, Sonosite TITAN® and Sonosite Turbo®, Sonosite, Bothell, WA, USA) [15,16].
During pregnancy, all women were scheduled for at least four antenatal visits which were equally
distributed during pregnancy, at week 20–22, week 26–28, week 32–34 and week 37–39. At all
antenatal visits, the women were monitored for anaemia (Hb < 11 g/dL), infections including malaria,
hypertensive disorders and anthropometric measurements were also collected. Weight was measured
while barefooted and wearing light clothes on a digital weighing scale. Height in centimetres was
measured with a stadiometer and BMI was defined as weight in kilograms divided by the square of the
height in meters (kg/m2). Mid-upper arm circumference (MUAC) was measured on the upper right
arm at the midpoint of the acromion process and the tip of the olecranon. Blood pressure was measured
by a digital blood pressure monitor (r-champion® N, Rudolf Riester, Jungingen, Germany) with an
inflatable cuff of an appropriate size after resting for at least 5 min [17]. Furthermore, the women were
screened with a urine dipstick for glucosuria as well as for polyhydramnios (defined as an amniotic
fluid index > 20) with transabdominal ultrasound.
In total, 538 women were included in the present study, of whom 392 women were screened with
an OGTT, with the majority being screened during weeks 32–34 of gestation. The OGTT was scheduled
for the antenatal visit in week 32–34, due to concerns about missing women with GDM if they were
screened at the previous visit in week 26–28. Most of the women had their visits in the first available
week, i.e., week 26 and week 32. Out of the 538 women, 77 had a miscarriage, 34 moved outside the
study area or withdrew their consents and the remaining 35 women either did not comply with the
overnight fasting criterion before the examination, missed their visit in the last trimester or gave birth
before week 32 (Figure 1). No differences in age, BMI, MUAC or Hb was observed between the women
who underwent an OGTT and the ones that were not tested (data not shown).
The OGTT was performed after 12-h of overnight fasting. Venous fasting blood samples were
taken and blood from the butterfly blood sampling tube was used to measure glucose immediately
using HemoCue® Glucose 201 RT (Ängelholm, Sweden). The coefficient of variation for the HemoCue
Glucose 201 has previously been shown to be 1.8%, and is almost as precise as the hexokinase laboratory
method [18].
Hereafter, each woman was instructed to drink a glucose solution containing 82.5 g monohydrate
glucose (corresponding to 75 g anhydrous glucose) (Rapra’s Pure Glucose, Instant Energy Plus,
Rapra Limited, Nairobi, Kenya) in 250 mL of water within 5 min. Thereafter, she was instructed to
be seated in the waiting area without drinking, eating or smoking for the following 2 h, where blood
glucose was measured by a fingerprick test after 1- and 2-h. If the OGTT was abnormal, the women
were given dietary advice and were controlled every third week for fasting blood glucose and glycated
haemoglobin (HbA1c) (Afinion AS 100 analyzer). If the women by mistake had not been fasting at their
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follow-up visit, random blood glucose was measured. Furthermore, ultrasound for foetal growth was
performed bi-weekly. A few of the women had more than one OGTT because there was a suspicion
of GDM early in pregnancy due to, for example, glucosuria and it was then repeated routinely at
weeks 32–34.
Gestational diabetes mellitus was diagnosed according to the WHO 2013 guidelines as follows:
fasting venous plasma glucose 5.1–6.9 mmol/L, or venous plasma 1-h glucose value ≥10 mmol/L or
2-h glucose value 8.5–11.0 mmol/L. In the present study, the fasting sample was taken from venous
blood whereas 1-h and 2-h samples were based on capillary blood. Using HemoCue® Glucose 201
RT (Ängelholm, Sweden), plasma-equivalent glucose levels were measured. A conversion factor for
whole blood-to-plasma glucose of 1.11 was used as recommended by the Internatinal Federation of
Clinical Chemistry IFCC [19]. The measurement based on capillary blood was converted using the
model by Colagiuri et al. and accordingly, the cut-off value for GDM was 10.7 mmol/L for 1-h values
and 9.15 mmol/L for 2-h values [20].
Haemoglobin levels were measured using Sysmex® KX-21N haematological analyser (Sysmex
Corporation, Kobe, Japan) on venous blood. Ferritin, albumin and bilirubin (Vista_1500 system)
and C-reactive protein (CRP) (Afinion AS 100 analyser) were measured. Further details on the
FOETALforNCD study have previously been published in [14].
4. Statistics and Ethics
Normally distributed data are presented as mean ±(SD) whereas skewed data are presented as
median and interquartile range. Differences between women diagnosed with GDM and non-GDM
controls were analysed using Student´s t-test for normally distributed data, Mann–Whitney U test
for non-normally distributed data or X2 test for categorical data. Pearson correlation analyses were
performed in order to explore the association between Hb and ferritin concentrations and fasting
glucose measurements at the time when the OGTT was carried out. Furthermore, correlation analyses
between Hb at inclusion (before week 11) and fasting glucose from the OGTT was carried out. p ≤ 0.05
was considered statistically significant. All statistical analyses were performed using SAS 9.4 statistical
software (SAS Institute, Cary, NC, USA).
Ethical clearance was granted by the Medical Research Coordinating Committee of the National
Institute for Medical Research (reference number NIMR/HQ/R.8a/Vol. IX/1717). After giving oral
information, written informed consent in Swahili (or thumbprints from illiterate women, given after
a witness who was not involved in the project was informed) was obtained prior to enrolment.
All procedures were conducted in accordance with the Declaration of Helsinki.
5. Results
Characteristics of women with GDM and non-GDM controls are presented in Table 1. Women
with GDM tended to be older. No difference in gestational age at delivery or birth weight was observed
between the two groups. Body mass index at inclusion (before week 11) was in the normal range
< 25 kg/m2 and no differences in family history of diabetes were found between the two groups
(Table 1). Very few had malaria at the time the OGTT was performed (10 GDM women and 12 controls).
Seven women, all in the GDM group, had type 2 diabetes diagnosed based on the OGTT during
pregnancy (fasting glucose ≥ 7 mmol/L or 2-h OGTT ≥ 11.1 mmol/L).
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Table 1. Characteristics of the women who underwent an OGTT.
GDM Cases Controls p-Value
n = 153 n = 239
Age (years) * 27 (22;35) 26 (22;33) 0.07
Parity (n: nulliparity/1 child/≥2
children) # 15/34/104 38/46/155 0.21
Ethnicity (n (%)) #
Sambaa 61 (39.9) 83 (34.7)
Zigua 47 (30.7) 81 (33.9)
Pare 11 (7.2) 15 (6.3)
Bondei 2 (1.3) 8 (3.3)
Other 32 (20.9) 52 (21.8) 0.65
Education (n (%)) #
None 11 (7.2) 24 (10.0)
Incomplete primary 23 (15.0) 32 (13.4)
Complete primary 103 (67.3) 161 (67.4)
Secondary or higher 16 (10.5) 22 (9.2) 0.76
Source of domestic water (n (%)) #
Tap 95 (62.1) 129 (54.0)
Well 22 (14.4) 37 (15.5)
River 33 (21.5) 65 (27.2)
Pond/pool 3 (2.0) 8 (3.3) 0.42
Type of toilet facility (n (%)) #
Flush 46 (30.3) 61 (25.5)
Pit 105 (69.1) 175 (73.2)
None 1 (0.6) 3 (1.3) 0.55
Family history of diabetes 12 (8.7) 19 (9.0) 0.93
BMI at inclusion (kg/m2) * 23.4 (20.9;26.9) 22.7 (20.5;25.6) 0.14
MUAC at inclusion (cm) * 27.5 (25.9;30.8) 27.5 (25.1;30.2) 0.27
Fasting glucose (OGTT) (mmol/L) 5.5 (0.6) 4.4 (0.4) -
1-h glucose (OGTT) (mmol/L) 7.5 (1.4) 6.6 (1.1) -
2-h glucose (OGTT) (mmol/L) 6.8 (1.1) 6.3 (0.9) -
Systolic BP (mmHg) 103.9 (9.97) 104.4 (11.75) 0.64
Diastolic BP (mmHg) 66.1 (8.0) 66.3 (9.3) 0.84
Pulse (beats per min.) 92.2 (12.1) 90.8 (11.2) 0.25
Hb (g/dL) 10.63 (1.32) 10.72 (1.27) 0.49
Albumin (g/dL) 28.0 (2.15) 27.72 (2.37) 0.29
Ferritin (ng/mL) * 9.3 (6.0;17.5) 8.5 (6.2;12) 0.19
CRP (mg/L) * 5.0 (5.0;5.0) 5.0 (5.0;5.0) 0.65
ALAT (U/L) * 13.9 (11.4;17.4) 14.0 (11.8;16.9) 0.90
Vitamin B12 (pmol/L) * 277 (216;370) 274 (205;340) 0.28
Folic acid (nmol/L) * 24.7 (16.6;35.6) 25.4 (16.1;38.4) 0.61
Bilirubin (µmol/L) * 6.0 (4.6;9.1) 5.7 (4.3;8.4) 0.28
Malaria 10 (6.5) 12 (5.1) 0.65
HIV seropositive 5 (3.3) 4 (1.7) 0.14
Gestational age at birth (weeks+days) 39+6 (1+4) 40+0 (1+4) 0.26
Birth weight (g) 3012 (539) 3014 (455) 0.97
Values are mean (SD), median (25th;75th percentiles) or n (%). p-values are calculated using student’s T-test,
Mann–Whitney U test * or X2 test #. The measurements have been obtained at time of OGTT if anything else is not
mentioned. Abbreviations: GDM: gestational diabetes, OGTT: oral glucose tolerance test, MUAC: mid upper arm
circumference, CRP: C-reactive protein, Hb: haemoglobin, BP: Blood pressure.
In total, 392 women completed an OGTT as described. Eighteen women had the OGTT performed
twice and one woman underwent an OGTT three times. If GDM was diagnosed in more than one
OGTT, blood glucose measurements from the first OGTT were included in the analyses. By the OGTT
screening, we found 153 women with GDM, i.e., a prevalence of 39.0% (95% CI: 34.2–44.1). The majority
(94.1%) were diagnosed based on the fasting blood sample (Table 2). While 64% of the women had
their OGTT performed in week 32+0 to 34+0, 18% had the OGTT before week 32+0 and 18% after week
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34+0. If only including women, who had their OGTT performed in week 31–34 (GA 217–238 days)
the GDM prevalence was 41% (124/300). Furthermore, no difference between GDM and controls
in gestational age at the time when the OGTT was preformed was observed (GDM: 32+5 (2+2) vs.
control 33+4 (2+2) weeks+days, p = 0.07). In the present study WHO diagnostic cut-points based
on the Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study were used. It has been
demonstrated that the protocol used in the HAPO study results in a mean plasma glucose drop of
approximately 0.2 mmol/L compared to samples immediately measured or using glycolytic inhibitors
that immediately stabilize glucose [21]. If we take this positive bias of 0.2 mmol into account and raise
the cut-off for GDM to 5.3 mmol/L in the present study, a GDM prevalence of 27.6% is found.
Table 2. Percent of GDM diagnosed by each glucose measure.
GDM Diagnosis Based upon: n % (95%-CI)
Fasting sample 144 94.1 (94.0;94.2)
2-h OGTT 5 3.3 (3.2;3.4)
Fasting sample and 1-h OGTT 3 2.0 (1.9;2.0)
Fasting sample and 1-h OGTT and 2-h OGTT 1 0.65 (0.61;0.70)
95%-CIs of the proportion are calculated using Wilson score method [22].
At the time of the OGTT, no differences in Hb, ferritin, CRP or albumin levels were seen between
the GDM and control groups (Table 1). In addition, no correlations between Hb and fasting glucose
(r = −0.08, p = 0.13) or between ferritin and fasting glucose (r = 0.09, p = 0.11) were found in the
combined group including both GDM and control women. When the women were analysed separately
according to GDM status, no correlations were seen between Hb and fasting glucose (GDM: r = −0.05,
p = 0.56 and non-GDM: r = −0.11, p = 0.11) or between ferritin levels and fasting glucose (GDM;
r = 0.04, p = 0.68 and non-GDM; r = 0.12, p = 0.13). There was a weak association between Hb at
inclusion and fasting glucose when the OGTT was performed (r = −0.09, p = 0.09). After adjustment
for age and BMI, the association became significant (β −0.06, p = 0.04).
6. Discussion
In rural Tanzania, we found a GDM prevalence of 39.0%. This prevalence is higher than what has
previously been found in SSA, including Tanzania. A systematic review including 22 studies from
SSA found a GDM prevalence of up to 14% [5]. However, all the reviewed studies included only six
of the total 47 countries from SSA and half of them were from Nigeria [5]. A recent study with data
collected during 2015–2016 in Moshi Town, Tanzania, reported a GDM prevalence of 19.5% using the
WHO/IADPSG 2013 criteria [8] which was similar to the criteria used in the present study. Some of
the discrepancies could be explained by differences in BMI and other body anthropometric indices
between the study populations or due to a poorer and unhealthier diet including a lower intake of
vegetables and more rice and bread among women from Korogwe and Handeni districts, which is
rural and a poorer area as compared with Moshi Town. It can also be speculated that a higher degree
of insulin resistance is present in our study population. Alanine aminotransferase (ALAT) is elevated
in most cases of non-alcohol fatty liver diseases and ALAT levels have been associated with decreased
insulin sensitivity in subjects with type 2 diabetes [23]. On the other hand, bilirubin may protect
against insulin resistance by reducing visceral fat [24]. Nevertheless, no differences in either ALAT or
bilirubin between the GDM women and control women were observed in the present study.
In the present study, 94.1% of all women were classified with GDM based on a fasting blood
sample. This finding is consistent with a large Danish study, where the majority of GDM cases were
also classified based on the fasting blood glucose value [25]. Furthermore, it is consistent with a large
population-based screening for GDM in North India, where more than 5000 women were screened
and more than 94% of GDM cases were identified based on the fasting blood glucose value [26].
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Interestingly, when frequencies of GDM were reported among the 15 centres that participated in
the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) study, a substantial centre-to-centre
variation was found in which the time-point of glucose measures met the diagnostic threshold for
GDM [27]. In places such as Bellflower and Providence in the USA and Barbados, more than 70% of
women were classified as GDM by fasting blood glucose, whereas the GDM diagnosis was based on
the 1-h value in 64% of the cases in Bangkok, and the 2-h value in 29% of the cases in Hong Kong.
This variation between centres has been suggested to be influenced by the degree of obesity and degree
of abnormal glucose tolerance in the general populations where the HAPO centres were located. Since
most of the women with GDM in the present study had their diagnosis based on the fasting values
rather than the OGTT, the applicability of an OGTT for the diagnosis of GDM can be questioned in
some low- and middle-income countries given its higher cost and being more time consuming [4].
Therefore, the one size fits all approach in relation to GDM diagnosis is debatable [25]. Accordingly,
in our setting in Korogwe, it might be recommendable to perform an accurate measure of fasting
blood sample and then only perform an OGTT in those without GDM diagnosed by a fasting blood
glucose value.
An ongoing debate is whether universal or selective screening for GDM is the most appropriate
approach. In a population from SSA it has been shown that approximately 20% of GDM cases defined by
WHO 2013 criteria would have been missed if a selective screening approach was used [28]. Risk-factor
based screening including pre-pregnancy BMI > 27 kg/m2, family history of diabetes, previous GDM,
previous baby >4500 g or glucosuria, followed by an OGTT is the current procedure in Denmark [29].
When the WHO 2013 criteria for diagnosing GDM by fasting values were applied to Danish women
without GDM, about 40% turned out to have GDM but had a low risk of pregnancy complications [25].
In the present Tanzanian population, there was no difference in family history of diabetes between
GDM and control women and 75% of the GDM women had BMI < 27 kg/m2; thus, it seems that when
possible, the thresholds for diagnosing GDM and the screening approach should be adopted to the
local setting.
In the present study, no associations (except for a weak association between Hb at inclusion
and fasting glucose from the OGTT after adjustment for age and BMI) between Hb or ferritin levels
and glucose concentrations were found. Previous studies have suggested that anaemia in pregnancy
increases the risk of GDM [9,30] whereas a recent meta-analysis based on six studies, reported that
pregnant women with iron-deficiency anaemia were 39% less likely to develop GDM [31]. These
discrepancies may be due to differences in study populations, diagnosis of GDM and timing of Hb
and ferritin measurements. Although the underlying mechanisms linking anaemia and GDM are still
unknown, various mechanisms have been suggested such as iron being a catalyst of several biochemical
reactions leading to production of reactive oxygen species which can decrease insulin sensitivity [32].
Others suggest that iron overload can be toxic to β-cells and thereby influence insulin secretion [33].
It has been speculated that the association between anaemia and increased risk for GDM may be
explained by a more general nutritional status including micronutrient deficiency among women with
GDM [31]. However, most women in our study had normal levels of folic acid and vitamin B12.
A limitation in the present study is that the majority of the OGTTs were performed during weeks
32–34, whereas most other studies have been testing for GDM during week 24–28. Since insulin
resistance increases during pregnancy, this later testing could contribute to our findings of a higher
GDM prevalence. However, during pregnancy, fasting glucose most likely decreases due to an increase
in plasma volume in early pregnancy and increased glucose utilization in later pregnancy by the
foeto-placental unit [34]. In line with this, there was a tendency towards a higher gestational age at the
time of OGTT among women without GDM compared to women with GDM. The majority of GDM
cases in the present study were diagnosed based on their fasting glucose value and we believe that
this late testing did not significantly influence our results. Even though the study participants in the
present study were thoroughly instructed on how to fast there is always a risk that instructions were
not followed. However, the fasting blood glucose values were similar, and the 1-h and 2-h glucose
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values were actually lower in the present study compared to a recent study from Ethiopia where they
found a GDM prevalence of 12.8%. This supports the notion that our study participants most likely
had been fasting. Finally, since the prevalence of diabetes in the pre-pregnancy cohort was previously
shown to be 0.8% [14] and the prevalence of type 2 diabetes in adults in Tanzania is 3.7% according
to the International Diabetes Federation (IDF) [35], it is not likely that the high prevalence of GDM
observed was due to a large proportion of undiagnosed type 2 diabetes.
Finally, the use of ferritin as a marker for iron deficiency can be challenging if not taking the
inflammatory state into account, since inflammation increases ferritin levels [36]. Thus, if iron deficiency
is associated with GDM, this might be masked in women with inflammation and “falsely” increased
ferritin levels. However, in the present study no difference in CRP was found between the groups.
In the present study, blood glucose was measured by HemoCue 201, where whole blood is
converted to plasma glucose concentrations. We are aware that the ratio between whole blood
and plasma depends on haematocrit and hydration status and therefore also that anaemia can be a
confounder for the glucose levels. However, since no association was found between Hb and glucose
levels, we do believe that adjustment for anaemia would not have significantly influenced GDM
prevalence in the present study. Furthermore, we are aware that even a small divergence in the way
of collecting samples such as using glycolytic inhibitors or on-point measurements, time of fasting,
measurement devices etc., cause marginal differences in blood glucose levels, and that small shifts in
fasting plasma glucose can translate into a large variation in GDM incidence. In the present study,
the sample collection and treatment were all conducted by trained project employees, using standard
operating procedures to ensure uniformity throughout the study, and blood samples were analysed
immediately which should reduce the bias. However, after having taken a possible positive bias into
account, the GDM prevalence was 27.6%, indicating the importance of where to set the cut-points for
diagnosis and that it may require revision if different pre-analytical protocols are used. Furthermore,
the use of point-of-care testing versus laboratory testing are also highly relevant to consider when
examining and comparing GDM prevalence. Malley et al. showed that the diagnostic accuracy of a
point-of-care measurement versus a laboratory measurement was 83% (74.2%–89.8%) [37], suggesting
that if the tests are performed in resource-rich settings, then the use of blood collection tubes containing
citrate that inhibits glycolysis followed by laboratory tests are preferable. However, in low-resource
settings such as Tanzania where this procedure is not always possible, it will be relevant to validate
point-of-care testing with laboratory testing if new screening procedures are going to be implemented.
Another limitation is that the study was designed to look at anaemia in early life and its impact on
foetal and placental development and risk for non-communicable disease later in life, not to examine
GDM prevalence per se. The present study was powered to detect an effect of −0.31 z-score on birth
weight in 2nd trimester severe anaemia (Hb ≤ 8 g/dL) with a significance level of 0.05, a power of
0.80, and an assumption of 15% lost to follow-up based upon previous observations in the STOPPAM
study [38]. Furthermore, we cannot exclude the possibility that the study is underpowered to detect a
potential association between Hb and ferritin and fasting glucose.
7. Conclusions
In conclusion, prevalence of GDM was high in rural North-Eastern Tanzania. We recommend an
introduction of routine screening for hyperglycemia in Tanzania. In view of the laborious, costly and
patient-unfriendly OGTT, alternative methods such as fasting blood glucose should be considered
when screening for GDM in low- and middle-income countries.
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